Congrats to our client Compugen on the completion of a $20M dollar PIPE by American bio-pharma company, BMS, marking and reinforcing the continuation of the strategic cooperation between two companies.
In return for the investment, BMS received 2.3 million Compugen shares at a price of $8.57 per share, representing a 33% premium on the closing price of the share prior to the date of completion.
Partner Shelly Blatt Zak and Associate Ivor Krumholtz represented Compugen, who is researching and developing immunotherapy medications for cancer.
Great work!
